Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
Status:
Completed
Trial end date:
2021-05-18
Target enrollment:
Participant gender:
Summary
The parallel three-group study of efficacy and safety was planned to investigate the
reduction in abdominal pain and bloating during treatment with the fixed-dose combination of
Mebeverine + Simethicone versus Duspatalin® and Espumisan® as a monotherapy (Protocol No.
MESI3001).